Boai NKY Pharmaceuticals Ltd (300109) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.038x

Based on the latest financial reports, Boai NKY Pharmaceuticals Ltd (300109) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥139.46 Million ≈ $20.41 Million USD) by net assets (CN¥3.69 Billion ≈ $540.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Boai NKY Pharmaceuticals Ltd balance sheet quality to measure how much of total assets are equity-financed.

Boai NKY Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Boai NKY Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Boai NKY Pharmaceuticals Ltd (300109) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Boai NKY Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Boai NKY Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Lighthouse Capital Ltd
JSE:LTE
0.026x
SDI Corp
TW:2351
0.077x
China Motor Corp
TW:2204
0.028x
Ningbo Peace Bird Fashion
SHG:603877
0.044x
Arctech Solar Holding Co Ltd
SHG:688408
0.068x
ASGN Inc
NYSE:ASGN
0.047x
Quechen Silicon Chemical Co. Ltd.
SHG:605183
0.047x
Welspun Enterprises Limited
NSE:WELENT
-0.147x

Annual Cash Flow Conversion Efficiency for Boai NKY Pharmaceuticals Ltd (2007–2025)

The table below shows the annual cash flow conversion efficiency of Boai NKY Pharmaceuticals Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Boai NKY Pharmaceuticals Ltd stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥3.66 Billion
≈ $534.86 Million
CN¥338.11 Million
≈ $49.48 Million
0.093x +30.34%
2024-12-31 CN¥3.61 Billion
≈ $527.92 Million
CN¥256.03 Million
≈ $37.47 Million
0.071x -48.84%
2023-12-31 CN¥3.52 Billion
≈ $515.09 Million
CN¥488.25 Million
≈ $71.45 Million
0.139x +71.74%
2022-12-31 CN¥3.12 Billion
≈ $456.15 Million
CN¥251.77 Million
≈ $36.84 Million
0.081x +532.17%
2021-12-31 CN¥3.40 Billion
≈ $497.55 Million
CN¥43.44 Million
≈ $6.36 Million
0.013x -85.27%
2020-12-31 CN¥3.08 Billion
≈ $450.15 Million
CN¥266.87 Million
≈ $39.05 Million
0.087x +232.53%
2019-12-31 CN¥3.05 Billion
≈ $446.69 Million
CN¥79.64 Million
≈ $11.65 Million
0.026x -31.79%
2018-12-31 CN¥1.28 Billion
≈ $186.75 Million
CN¥48.81 Million
≈ $7.14 Million
0.038x +5.36%
2017-12-31 CN¥1.30 Billion
≈ $190.58 Million
CN¥47.28 Million
≈ $6.92 Million
0.036x -60.99%
2016-12-31 CN¥1.23 Billion
≈ $179.49 Million
CN¥114.14 Million
≈ $16.70 Million
0.093x +68.78%
2015-12-31 CN¥1.16 Billion
≈ $170.16 Million
CN¥64.12 Million
≈ $9.38 Million
0.055x -52.64%
2014-12-31 CN¥400.25 Million
≈ $58.57 Million
CN¥46.60 Million
≈ $6.82 Million
0.116x +89.44%
2013-12-31 CN¥377.06 Million
≈ $55.18 Million
CN¥23.17 Million
≈ $3.39 Million
0.061x +8.28%
2012-12-31 CN¥363.81 Million
≈ $53.24 Million
CN¥20.65 Million
≈ $3.02 Million
0.057x +405.33%
2011-12-31 CN¥350.93 Million
≈ $51.35 Million
CN¥3.94 Million
≈ $576.77K
0.011x -62.77%
2010-12-31 CN¥333.21 Million
≈ $48.76 Million
CN¥10.05 Million
≈ $1.47 Million
0.030x -93.44%
2009-12-31 CN¥62.14 Million
≈ $9.09 Million
CN¥28.57 Million
≈ $4.18 Million
0.460x +593.63%
2008-12-31 CN¥43.93 Million
≈ $6.43 Million
CN¥-4.09 Million
≈ $-598.80K
-0.093x -117.36%
2007-12-31 CN¥17.82 Million
≈ $2.61 Million
CN¥9.56 Million
≈ $1.40 Million
0.536x --

About Boai NKY Pharmaceuticals Ltd

SHE:300109 China Specialty Chemicals
Market Cap
$897.61 Million
CN¥6.13 Billion CNY
Market Cap Rank
#9262 Global
#2286 in China
Share Price
CN¥12.69
Change (1 day)
+2.84%
52-Week Range
CN¥12.02 - CN¥20.47
All Time High
CN¥149.39
About

Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP), Orarez, and in vitro diagnostic products, as well as invests in tumor drugs. It offers its products for pharmaceutical products, such as APIs and excipients; personal care products, including cosmetics, haircare, or… Read more